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Merkel cell carcinoma (MCC) is a highly aggressive skin
cancer induced through oncogenic transformation by the
Merkel cell polyomavirus (MCPyV). Intratumoral CD8
T cell infiltration and the immunogenic capacity of the
host have been strongly correlated to survival in patients
with MCC. The MCPyV oncoproteins represent highly
attractive targets for immunotherapy of MCC, being both
foreign to the host and specific for the infection. We have
mapped the T cell recognition of MCPyV by use of a
novel technology platform for T-cell enrichment and com-
binatorial encoding of histocompatibility antigen (HLA)
class I multimers. We investigated the T cell recognition
of both the oncogenic proteins, Large and Small T antigen
and the capsid protein VP1 that is profoundly expressed
also in the non-symptomatic MCPyV infected healthy
individuals. We investigated the T cell recognition of 398
in silico predicted HLA-ligands from Large T, Small T and
VP1 and identified T-cell responses restricted to HLA-A1,
A2, A3, A11 and B7. Numerous T cell responses were
detected against MCPyV in both healthy donors and MCC
patients, with a striking observation that T cell responses
against Large and Small T antigens were found exclusively
in MCC patients, suggesting that these oncoproteins
are only presented to the immune system in the tumor-
bearing host and represent highly specific targets for
cancer immunotherapy of MCC. Importantly, we show for
three different epitopes that MCC specific T cells are
capable of killing target cells expressing Large T antigen,
including HLA-matched MCC cell lines, indicating that
these T cells could provide functional activity upon in vivo
transfer, and thus be employed in adoptive T cell therapy
for MCC. T cell epitopes from Large T antigen of MCPyV
display a large sequence variation with other polyoma-
viruses, but are highly conserved among different strains
of MCPyV. Targeting these epitopes are therefore likely
to lead to specific recognition of the tumor cells bearing
the Large T integration - that is essential for growth and
survival of the tumor cells.
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